



Clinical trial results:

A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHT Study)

Summary

EudraCT number	2014-002111-41
Trial protocol	ES DE BE NL GB NO IE PT GR FR RO IT
Global end of trial date	

Results information

Result version number	v1
This version publication date	18 August 2018
First version publication date	18 August 2018

Trial information

Trial identification

Sponsor protocol code	205888
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	Other Identifier: Bristol-Myers Squibb: AI438-047

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	14 May 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 August 2016
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this Phase 3 study is to demonstrate that fostemsavir 600 mg BID has superior efficacy compared to placebo when given in combination with a failing background regimen over a period of 7 days in HIV-1 infected HTE adults with multi-drug resistance.

Protection of trial subjects:

Not applicable

Background therapy:

Participants continued to receive their current failing antiretroviral regimen along with fostemsavir 600 mg BID or placebo during the double-blind period. During open-label period, participants received an optimized background therapy along with fostemsavir 600 mg BID.

Evidence for comparator: -

Actual start date of recruitment	13 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 38
Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Brazil: 64
Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Chile: 11
Country: Number of subjects enrolled	Colombia: 1
Country: Number of subjects enrolled	France: 15
Country: Number of subjects enrolled	Germany: 10
Country: Number of subjects enrolled	Greece: 4
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Italy: 23
Country: Number of subjects enrolled	Mexico: 15
Country: Number of subjects enrolled	Peru: 5
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Portugal: 5
Country: Number of subjects enrolled	Puerto Rico: 5
Country: Number of subjects enrolled	Romania: 9
Country: Number of subjects enrolled	South Africa: 4
Country: Number of subjects enrolled	Spain: 6

Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	United States: 136
Worldwide total number of subjects	371
EEA total number of subjects	79

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	1
Adults (18-64 years)	358
From 65 to 84 years	12
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This was a 2 cohort Phase 3 study conducted in heavily treatment experienced (HTE) participants infected with multi-drug resistant human immunodeficiency virus (HIV)-1. Based on the number of fully active and available antiretroviral drug classes at Screening, participants were assigned to either Randomized Cohort or Non-randomized Cohort.

Pre-assignment

Screening details:

A total of 731 participants were screened, of which 371 were included in either Randomized Cohort (fostemsavir or placebo) or Non-randomized Cohort (fostemsavir) and received at least one dose of study treatment. The study was conducted in 24 countries. The results presented are based on the Week 48 Interim Analysis.

Period 1

Period 1 title	Double-blind Period-Up to 8 days
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Randomized Cohort-Placebo

Arm description:

HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants were administered one tablet of fostemsavir matched placebo twice daily with or without food.

Arm title	Randomized Cohort-fostemsavir 600 mg BID
------------------	--

Arm description:

HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.

Arm type	Experimental
Investigational medicinal product name	Fostemsavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants were administered one 600 milligram (mg) tablet of fostemsavir twice daily with or without food.

Arm title	Non-randomized Cohort-fostemsavir 600 mg BID
------------------	--

Arm description:

HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.

Arm type	Experimental
Investigational medicinal product name	Fostemsavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants were administered one 600 milligram (mg) tablet of fostemsavir twice daily with or without food.

Number of subjects in period 1	Randomized Cohort- Placebo	Randomized Cohort- fostemsavir 600 mg BID	Non-randomized Cohort-fostemsavir 600 mg BID
Started	69	203	99
Completed	68	198	99
Not completed	1	5	0
Adverse event, non-fatal	-	2	-
Death	1	1	-
No longer meets study criteria	-	1	-
Lost to follow-up	-	1	-

Period 2

Period 2 title	Open label Period-Up to atleast 96 weeks
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Randomized Cohort-Placebo
Arm description:	
HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).	
Arm type	Experimental
Investigational medicinal product name	Fostemsavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants were administered one 600 milligram (mg) tablet of fostemsavir twice daily with or without food.	
Arm title	Randomized Cohort-fostemsavir 600 mg BID

Arm description:	
HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.	
Arm type	Experimental
Investigational medicinal product name	Fostemsavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants were administered one 600 milligram (mg) tablet of fostemsavir twice daily with or without food.	
Arm title	Non-randomized Cohort-fostemsavir 600 mg BID

Arm description:	
HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.	
Arm type	Experimental
Investigational medicinal product name	Fostemsavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants were administered one 600 milligram (mg) tablet of fostemsavir twice daily with or without food.	

Number of subjects in period 2	Randomized Cohort- Placebo	Randomized Cohort- fostemsavir 600 mg BID	Non-randomized Cohort-fostemsavir 600 mg BID
Started	68	198	99
Completed	0	0	0
Not completed	68	198	99
Adverse event, serious fatal	1	2	1
Consent withdrawn by subject	-	5	1
Adverse event, non-fatal	2	2	4
Death	1	5	12
Ongoing	55	160	67
Pregnancy	-	1	-
Non-compliance with study drug	3	8	5
No longer meets study criteria	-	2	2
Lost to follow-up	3	3	1
Progression of disease	-	1	-
Lack of efficacy	3	9	6

Baseline characteristics

Reporting groups

Reporting group title	Randomized Cohort-Placebo
Reporting group description:	
HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).	
Reporting group title	Randomized Cohort-fostemsavir 600 mg BID
Reporting group description:	
HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.	
Reporting group title	Non-randomized Cohort-fostemsavir 600 mg BID
Reporting group description:	
HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.	

Reporting group values	Randomized Cohort-Placebo	Randomized Cohort-fostemsavir 600 mg BID	Non-randomized Cohort-fostemsavir 600 mg BID
Number of subjects	69	203	99
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	43.0	45.2	48.1
standard deviation	± 11.02	± 12.72	± 11.53
Gender categorical			
Units: Subjects			
Female	12	60	10
Male	57	143	89
Race/Ethnicity, Customized			
Units: Subjects			
African American/African Heritage	18	42	23
American Indian or Alaska Native	1	6	1
Asian	0	2	0
Native Hawaiian or other Pacific islander	0	1	0
White	47	137	73
Mixed	1	6	1
Hispanic	1	2	1
Mestizo	1	2	0
North African	0	1	0
Mulatto	0	1	0

Brown	0	2	0
White and African descent	0	1	0

Reporting group values	Total		
Number of subjects	371		
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	82		
Male	289		
Race/Ethnicity, Customized			
Units: Subjects			
African American/African Heritage	83		
American Indian or Alaska Native	8		
Asian	2		
Native Hawaiian or other Pacific islander	1		
White	257		
Mixed	8		
Hispanic	4		
Mestizo	3		
North African	1		
Mulatto	1		
Brown	2		
White and African descent	1		

End points

End points reporting groups

Reporting group title	Randomized Cohort-Placebo
Reporting group description: HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).	
Reporting group title	Randomized Cohort-fostemsavir 600 mg BID
Reporting group description: HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.	
Reporting group title	Non-randomized Cohort-fostemsavir 600 mg BID
Reporting group description: HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.	
Reporting group title	Randomized Cohort-Placebo
Reporting group description: HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).	
Reporting group title	Randomized Cohort-fostemsavir 600 mg BID
Reporting group description: HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.	
Reporting group title	Non-randomized Cohort-fostemsavir 600 mg BID
Reporting group description: HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.	
Subject analysis set title	Randomized cohort
Subject analysis set type	Intention-to-treat
Subject analysis set description: HTE HIV-1 infected participants with ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks	

Primary: Mean change in logarithm to the base 10 (log10) HIV-1 ribonucleic acid (RNA) from Day 1 at Day 8-Randomized Cohort

End point title	Mean change in logarithm to the base 10 (log10) HIV-1 ribonucleic acid (RNA) from Day 1 at Day 8-Randomized Cohort ^[1]
-----------------	---

End point description:

Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window. Participants with missing Day 1 HIV-1 RNA values were not analyzed.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 and Day 8

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This end point is evaluated only in the Randomized cohort as pre-specified in the protocol and reporting and analysis plan.

End point values	Randomized Cohort-Placebo	Randomized Cohort-fostemsavir 600 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	69 ^[2]	201 ^[3]		
Units: Log10 copies per milliliter (c/mL)				
least squares mean (confidence interval 95%)				
Log10 copies per milliliter (c/mL)	-0.166 (-0.326 to -0.007)	-0.791 (-0.885 to -0.698)		

Notes:

[2] - ITT-E Population

[3] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical analysis 1
----------------------------	------------------------

Statistical analysis description:

Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.

Comparison groups	Randomized Cohort-fostemsavir 600 mg BID v Randomized Cohort-Placebo
Number of subjects included in analysis	270
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[4]
Method	ANCOVA
Parameter estimate	Mean difference (net)
Point estimate	-0.625

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.81
upper limit	-0.441

Notes:

[4] - Hypothesis test: $\mu_{\text{fostemsavir}} = \mu_{\text{Placebo}}$ where μ is a common intercept.

Secondary: Percentage of participants with HIV-1 RNA decreases from Day 1 that exceed 0.5 log₁₀ c/mL and 1.0 log₁₀ c/mL at Day 8-Randomized cohort

End point title	Percentage of participants with HIV-1 RNA decreases from Day 1 that exceed 0.5 log ₁₀ c/mL and 1.0 log ₁₀ c/mL at Day 8-Randomized cohort ^[5]
-----------------	--

End point description:

The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log₁₀ c/mL and 1.0 log₁₀ c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 and Day 8

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point is evaluated only in the Randomized cohort as pre-specified in the protocol and reporting and analysis plan.

End point values	Randomized Cohort-Placebo	Randomized Cohort-fostemsavir 600 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	69 ^[6]	203 ^[7]		
Units: Percentage of participants				
number (confidence interval 95%)				
>0.5 log ₁₀ c/mL	18.84 (11.35 to 29.61)	64.53 (57.74 to 70.79)		
>1.0 log ₁₀ c/mL	10.14 (5.00 to 19.49)	45.81 (39.10 to 52.68)		

Notes:

[6] - ITT-E Population

[7] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical analysis 1
----------------------------	------------------------

Statistical analysis description:

Difference between treatment groups (fostemsavir 600 mg BID-Placebo) and 95% confidence interval using Newcombe method is presented for >0.5 log₁₀ c/mL.

Comparison groups	Randomized Cohort-Placebo v Randomized Cohort-fostemsavir 600 mg BID
-------------------	--

Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	45.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.95
upper limit	55.45

Statistical analysis title	Statistical analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Difference between treatment groups (fostemsavir 600 mg BID-Placebo) and 95% confidence interval using Newcombe method is presented for $>1.0 \log_{10} \text{ c/mL}$.

Comparison groups	Randomized Cohort-Placebo v Randomized Cohort-fostemsavir 600 mg BID
Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	35.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	24.16
upper limit	44.25

Secondary: Percentage of participants with HIV-1 RNA <40 c/mL at Weeks 24 and 48-Randomized Cohort

End point title	Percentage of participants with HIV-1 RNA <40 c/mL at Weeks 24 and 48-Randomized Cohort
-----------------	---

End point description:

The durability of response (that is, the number of participants achieving HIV-1 RNA <40 c/mL) at Weeks 24 and 48 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24 and 48 or those who changed OBT due to lack of efficacy through Weeks 24 and 48 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA <40 c/mL) at Weeks 24 and 48 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 24 and 48

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[8]			
Units: Percentage of participants				
number (confidence interval 95%)				
Week 24	53 (47.0 to 58.8)			
Week 48	54 (47.7 to 59.5)			

Notes:

[8] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with on-treatment serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation (AELD)-Randomized Cohort

End point title	Number of participants with on-treatment serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation (AELD)-Randomized Cohort
-----------------	---

End point description:

An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48 analysis cut-off date

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[9]			
Units: Participants				
SAE	85			
AELD	14			

Notes:

[9] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with toxicity grade increase in clinical chemistry

results to Grade 3-4 relative to Baseline-Randomized Cohort

End point title	Number of participants with toxicity grade increase in clinical chemistry results to Grade 3-4 relative to Baseline-Randomized Cohort
-----------------	---

End point description:

Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and up to Week 48 analysis cut-off date

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[10]			
Units: Participants				
Albumin; n=268	1			
Alkaline phosphatase; n=268	3			
Alanine aminotransferase; n=268	13			
Amylase; n=268	2			
Aspartate aminotransferase; n=268	9			
Bicarbonate; n=268	1			
Direct bilirubin; n=268	19			
Bilirubin; n=268	6			
Calcium; n=268	9			
Cholesterol; n=221	10			
Creatine kinase; n=268	6			
Creatinine; n=268	43			
Estimated creatinine clearance; n=268	69			
Glucose/hyperglycemia; n=267	6			
Glucose/hypoglycemia; n=267	1			
Potassium/hyperkalemia; n=268	3			
Potassium/hypokalemia; n=268	0			
Low density lipoprotein (LDL) cholesterol; n=216	7			
Lipase; n=268	12			
Sodium/hyponatremia; n=268	0			
Sodium/hyponatremia; n=268	0			
Triglycerides; n=221	10			
Urate; n=268	7			

Notes:

[10] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with toxicity grade increase in hematology results to Grade 3-4 relative to Baseline-Randomized Cohort

End point title	Number of participants with toxicity grade increase in hematology results to Grade 3-4 relative to Baseline-Randomized Cohort
-----------------	---

End point description:

Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and up to Week 48 analysis cut-off date

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[11]			
Units: Participants				
Hemoglobin; n=268	14			
Neutrophils; n=268	8			
Platelets; n=267	2			
Leukocytes; n=268	4			

Notes:

[11] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with Centers for Disease Control (CDC) Class C events-Randomized Cohort

End point title	Number of participants with Centers for Disease Control (CDC) Class C events-Randomized Cohort
-----------------	--

End point description:

Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48 analysis cut-off date

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[12]			
Units: Participants				
Participants	24			

Notes:

[12] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Day 1 in cluster of differentiation (CD) 4+ T-cell count at Day 8-Randomized Cohort

End point title	Change from Day 1 in cluster of differentiation (CD) 4+ T-cell count at Day 8-Randomized Cohort ^[13]
-----------------	---

End point description:

CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 and Day 8

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point is evaluated only in the Randomized cohort as pre-specified in the protocol and reporting and analysis plan.

End point values	Randomized Cohort-Placebo	Randomized Cohort-fostemsavir 600 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	69 ^[14]	196 ^[15]		
Units: Cells per cubic millimeter				
least squares mean (confidence interval 95%)				
Cells per cubic millimeter	18.9 (4.7 to 33.0)	18.5 (10.1 to 26.8)		

Notes:

[14] - ITT-E Population

[15] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical analysis 1
-----------------------------------	------------------------

Statistical analysis description:

Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.

Comparison groups	Randomized Cohort-Placebo v Randomized Cohort-fostemsavir 600 mg BID
Number of subjects included in analysis	265
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.8
upper limit	16

Secondary: Change in CD4+ T- cell count percentage from Day 1 at Day 8- Randomized Cohort

End point title	Change in CD4+ T- cell count percentage from Day 1 at Day 8- Randomized Cohort ^[16]
-----------------	--

End point description:

CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 and Day 8

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point is evaluated only in the Randomized cohort as pre-specified in the protocol and reporting and analysis plan.

End point values	Randomized Cohort-Placebo	Randomized Cohort-fostemsavir 600 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	69 ^[17]	196 ^[18]		
Units: Percentage of CD4+T- cells				
least squares mean (confidence interval 95%)				
Percentage of CD4+T- cells	0.243 (-0.216 to 0.703)	0.860 (0.588 to 1.133)		

Notes:

[17] - ITT-E Population

[18] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.	
Comparison groups	Randomized Cohort-Placebo v Randomized Cohort-fostemsavir 600 mg BID
Number of subjects included in analysis	265
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	0.617
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.082
upper limit	1.151

Secondary: Change from Baseline in log10 HIV-1 RNA for fostemsavir when given with OBT through Week 48-Randomized Cohort

End point title	Change from Baseline in log10 HIV-1 RNA for fostemsavir when given with OBT through Week 48-Randomized Cohort
-----------------	---

End point description:

Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and up to Week 48

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[19]			
Units: Log10 c/mL				
arithmetic mean (standard deviation)				
Day 8; n=262	-0.656 (± 0.7536)			
Week 4; n=262	-2.051 (± 1.0717)			
Week 8; n=256	-2.207 (± 1.1416)			
Week 12; n=248	-2.237 (± 1.2105)			
Week 16; n=249	-2.277 (± 1.2834)			
Week 24; n=246	-2.297 (± 1.2788)			

Week 36; n=238	-2.332 (\pm 1.2265)			
Week 48; n=233	-2.324 (\pm 1.2876)			

Notes:

[19] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CD4+ T- cell count through Week 48-Randomized Cohort

End point title	Change from Baseline in CD4+ T- cell count through Week 48-Randomized Cohort
-----------------	--

End point description:

CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and up to Week 48

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[20]			
Units: Cells per cubic millimeter				
arithmetic mean (standard deviation)				
Day 8; n=255	19.8 (\pm 60.98)			
Week 4; n=259	48.9 (\pm 131.75)			
Week 8; n=254	61.5 (\pm 113.47)			
Week 12; n=249	79.0 (\pm 123.31)			
Week 16; n=245	84.1 (\pm 107.26)			
Week 24; n=247	90.4 (\pm 112.10)			
Week 36; n=234	109.7 (\pm 119.50)			
Week 48; n=228	138.9 (\pm 135.06)			

Notes:

[20] - ITT-E Population

Statistical analyses

Secondary: Change from Baseline in CD4+ T- cell count percentage through Week 48

End point title	Change from Baseline in CD4+ T- cell count percentage through Week 48
-----------------	---

End point description:

CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and up to Week 48

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	272 ^[21]			
Units: Percentage of CD4+ T- cells				
arithmetic mean (standard deviation)				
Day 8; n=255	0.75 (± 1.970)			
Week 4; n=259	2.30 (± 4.643)			
Week 8; n=254	2.36 (± 4.392)			
Week 12; n=249	3.00 (± 4.945)			
Week 16; n=245	3.51 (± 4.979)			
Week 24; n=247	4.26 (± 4.828)			
Week 36; n=234	5.06 (± 5.256)			
Week 48; n=228	6.51 (± 5.531)			

Notes:

[21] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with treatment-emergent viral genotypic substitution of interest in the GP160 domain as a measure of genotypic resistance-Randomized Cohort

End point title	Number of participants with treatment-emergent viral genotypic substitution of interest in the GP160 domain as a measure of genotypic resistance-Randomized Cohort
-----------------	--

End point description:

Plasma samples were collected for drug resistance testing. Participants with emergent viral genotypic substitutions of interest in GP160 domain was identified by next-generation sequencing (NGS) assay. Virologic failure (VF) Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. Criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA ≥ 400 c/mL at any time after prior confirmed suppression to <400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, >1 log₁₀ c/mL increase in HIV-1 RNA at any time above nadir level where nadir is

>=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA >=400 c/mL at or after Week 24. All participants received fostemsavir during open-label period irrespective of original randomization; hence, combined totals for Randomized Cohort is presented.

End point type	Secondary
End point timeframe:	
Week 48	

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	47 ^[22]			
Units: Participants				
Participants	20			

Notes:

[22] - VF Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with indicated fold change ratio (FCR) using the Monogram PhenoSense Entry Assay-Randomized Cohort

End point title	Number of participants with indicated fold change ratio (FCR) using the Monogram PhenoSense Entry Assay-Randomized Cohort
-----------------	---

End point description:

The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC₅₀, i.e., the ratio of the 50% inhibitory concentration (IC₅₀) of the clinical isolate to the IC₅₀ of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR<1 indicates that FC is smaller on-treatment than at Baseline. FCR >3 indicates that on-treatment FC is 3 times greater than it was at Baseline. Only participants available at the specified time point were analyzed. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.

End point type	Secondary
End point timeframe:	
Week 48	

End point values	Randomized cohort			
Subject group type	Subject analysis set			
Number of subjects analysed	44 ^[23]			
Units: Participants				
<=1	15			
>1 to 3	8			
>3 to 10	4			
>10 to 100	1			
>100 to 3000	9			
>3000	7			

Notes:

[23] - VF Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

On-treatment non-SAEs and SAEs were collected from start of study treatment until Week 48 data cut-off date. For Randomized Cohort-Placebo and Randomized Cohort-fostemsavir 600 mg BID, non-SAEs and SAEs during double-blind period (upto Day8) is presented.

Adverse event reporting additional description:

Non-SAEs and SAEs were collected in the Safety Population which comprised of all participants who received at least one dose of study treatment. One participant was excluded from the Total fostemsavir population as the participant took only placebo and had discontinued during the double-blind period.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	Randomized Cohort-Placebo
-----------------------	---------------------------

Reporting group description:

This reporting group includes HTE HIV-1 infected participants who were assigned to the Randomized Cohort and randomized to placebo twice daily (BID) along with their currently failing antiretroviral regimen for the double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID and an optimized background therapy (OBT). Randomized Cohort participants are assigned based on their screening status of having ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen. The data reported are safety events during the 8-day double-blind period.

Reporting group title	Randomized Cohort-fostemsavir 600 mg BID
-----------------------	--

Reporting group description:

This reporting group includes HTE HIV-1 infected participants who were assigned to the Randomized Cohort and randomized to fostemsavir 600 mg BID along with their currently failing antiretroviral regimen for the double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID and OBT. Randomized Cohort participants are assigned based on their screening status of having ≤ 2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen. The data reported are safety events during the 8-day double-blind period.

Reporting group title	Randomized Cohort-Total
-----------------------	-------------------------

Reporting group description:

This reporting group includes all participants in the Randomized Cohort. The data reported are safety events during fostemsavir dosing until the Week 48 data cut-off date.

Reporting group title	Non-randomized Cohort-fostemsavir 600 mg BID
-----------------------	--

Reporting group description:

This reporting group includes HTE HIV-1 infected participants who were assigned to the Non-randomized Cohort and received fostemsavir 600 mg BID and OBT. Non-randomized Cohort participants are assigned based on their screening status of having no remaining classes of fully active antiretroviral that can be combined in a new drug regimen. The data reported are safety events during fostemsavir dosing until the Week 48 data cut-off date.

Reporting group title	Total fostemsavir
-----------------------	-------------------

Reporting group description:

This reporting group included all enrolled participants (Randomized Cohort and Non-randomized Cohort) and who received fostemsavir 600 mg during the open-label period. The data reported are safety events during fostemsavir dosing until the Week 48 data cut-off date.

Serious adverse events	Randomized Cohort- Placebo	Randomized Cohort- fostemsavir 600 mg BID	Randomized Cohort- Total
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 69 (2.90%)	5 / 203 (2.46%)	85 / 271 (31.37%)
number of deaths (all causes)	1	1	10
number of deaths resulting from adverse events	1	1	9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	3 / 271 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Anal squamous cell carcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal cancer metastatic			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital warts			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma recurrent			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kaposi's sarcoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratoacanthoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung squamous cell carcinoma stage IV			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer metastatic			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile squamous cell carcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Foetal growth restriction			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adverse event			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial pain			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Immune reconstitution inflammatory syndrome			
subjects affected / exposed	0 / 69 (0.00%)	1 / 203 (0.49%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	1 / 1	1 / 1
Hypersensitivity			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast			

disorders			
Prostatitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical dysplasia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal polyps			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal oedema			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	1 / 69 (1.45%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranoia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schizophrenia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood HIV RNA increased			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood triglycerides increased			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial bypass thrombosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Burns third degree			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney rupture			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Open fracture			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shunt thrombosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	3 / 271 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulseless electrical activity			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar infarction			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mononeuropathy			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasticity			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	4 / 271 (1.48%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal pain			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal ulcer			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital dysplasia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammatory bowel disease			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malabsorption			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	1 / 69 (1.45%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reactive gastropathy			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 69 (0.00%)	2 / 203 (0.99%)	12 / 271 (4.43%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cellulitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	5 / 271 (1.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	3 / 271 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sepsis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus colitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 69 (0.00%)	1 / 203 (0.49%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIV-associated neurocognitive disorder			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	2 / 271 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pseudomonal sepsis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Abdominal wall abscess			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anorectal cellulitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bacterial sepsis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bronchitis			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis bacterial			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus chorioretinitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated cytomegaloviral infection			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated tuberculosis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis B reactivation			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histoplasmosis disseminated			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis coccidioides			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningoencephalitis viral			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Orchitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis acute			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella bacteraemia			
subjects affected / exposed	0 / 69 (0.00%)	1 / 203 (0.49%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic rash			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculosis liver			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	1 / 271 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			

subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cachexia			
subjects affected / exposed	1 / 69 (1.45%)	0 / 203 (0.00%)	0 / 271 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Non-randomized Cohort-fostemsavir 600 mg BID	Total fostemsavir	
Total subjects affected by serious adverse events			
subjects affected / exposed	44 / 99 (44.44%)	129 / 370 (34.86%)	
number of deaths (all causes)	14	24	
number of deaths resulting from adverse events	12	21	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma			
subjects affected / exposed	1 / 99 (1.01%)	4 / 370 (1.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Anal squamous cell carcinoma			

subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hodgkin's disease			
subjects affected / exposed	2 / 99 (2.02%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal cancer metastatic			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anogenital warts			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma recurrent			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kaposi's sarcoma			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Keratoacanthoma			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung squamous cell carcinoma stage IV			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Malignant melanoma			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer metastatic			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile squamous cell carcinoma			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Uterine leiomyoma			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	2 / 99 (2.02%)	3 / 370 (0.81%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			

Foetal growth restriction			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 99 (2.02%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adverse event			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Chest pain			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial pain			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Generalised oedema			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Immune reconstitution inflammatory syndrome			
subjects affected / exposed	1 / 99 (1.01%)	3 / 370 (0.81%)	
occurrences causally related to treatment / all	1 / 1	3 / 3	
deaths causally related to treatment / all	0 / 0	1 / 1	
Hypersensitivity			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical dysplasia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal oedema			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	0 / 99 (0.00%)	0 / 370 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 99 (0.00%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disorientation			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranoia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schizophrenia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood HIV RNA increased			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood triglycerides increased			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass thrombosis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns third degree			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney rupture			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open fracture			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt thrombosis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 99 (0.00%)	3 / 370 (0.81%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulseless electrical activity			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Seizure			
subjects affected / exposed	2 / 99 (2.02%)	3 / 370 (0.81%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mononeuropathy			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasticity			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 99 (0.00%)	4 / 370 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 99 (0.00%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal ulcer			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anogenital dysplasia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammatory bowel disease			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malabsorption			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reactive gastropathy			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 99 (0.00%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	2 / 99 (2.02%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Cholecystitis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 99 (3.03%)	5 / 370 (1.35%)	
occurrences causally related to treatment / all	0 / 3	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Nephrolithiasis			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			

subjects affected / exposed	2 / 99 (2.02%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lumbar spinal stenosis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	3 / 99 (3.03%)	15 / 370 (4.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cellulitis			
subjects affected / exposed	3 / 99 (3.03%)	8 / 370 (2.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	1 / 99 (1.01%)	4 / 370 (1.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	3 / 99 (3.03%)	4 / 370 (1.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sepsis			
subjects affected / exposed	3 / 99 (3.03%)	4 / 370 (1.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 2	
Chronic sinusitis			
subjects affected / exposed	1 / 99 (1.01%)	3 / 370 (0.81%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus colitis			

subjects affected / exposed	2 / 99 (2.02%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 99 (0.00%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIV-associated neurocognitive disorder			
subjects affected / exposed	0 / 99 (0.00%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral candidiasis			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 99 (0.00%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pseudomonal sepsis			
subjects affected / exposed	1 / 99 (1.01%)	2 / 370 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Abdominal wall abscess			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorectal cellulitis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bacterial sepsis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bronchitis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus chorioretinitis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated cytomegaloviral infection			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Disseminated tuberculosis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B reactivation			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Histoplasmosis disseminated			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis coccidioides			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningoencephalitis viral			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Orchitis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			

subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia cytomegaloviral			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella bacteraemia			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic rash			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Septic shock			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis liver			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 99 (0.00%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			

subjects affected / exposed	1 / 99 (1.01%)	1 / 370 (0.27%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cachexia			
subjects affected / exposed	0 / 99 (0.00%)	0 / 370 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Randomized Cohort- Placebo	Randomized Cohort- fostemsavir 600 mg BID	Randomized Cohort- Total
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 69 (23.19%)	48 / 203 (23.65%)	207 / 271 (76.38%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	10 / 271 (3.69%)
occurrences (all)	0	0	12
Skin papilloma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 203 (0.00%)	6 / 271 (2.21%)
occurrences (all)	0	0	6
Nervous system disorders			
Headache			
subjects affected / exposed	5 / 69 (7.25%)	8 / 203 (3.94%)	34 / 271 (12.55%)
occurrences (all)	5	8	50
Dizziness			
subjects affected / exposed	1 / 69 (1.45%)	2 / 203 (0.99%)	15 / 271 (5.54%)
occurrences (all)	1	2	15
Neuropathy peripheral			
subjects affected / exposed	0 / 69 (0.00%)	1 / 203 (0.49%)	6 / 271 (2.21%)
occurrences (all)	0	1	7
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 69 (1.45%)	1 / 203 (0.49%)	24 / 271 (8.86%)
occurrences (all)	1	1	36

Fatigue subjects affected / exposed occurrences (all)	3 / 69 (4.35%) 3	3 / 203 (1.48%) 3	17 / 271 (6.27%) 18
Asthenia subjects affected / exposed occurrences (all)	2 / 69 (2.90%) 2	2 / 203 (0.99%) 2	11 / 271 (4.06%) 12
Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	1 / 271 (0.37%) 1
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	3 / 69 (4.35%) 3	11 / 203 (5.42%) 11	58 / 271 (21.40%) 79
Nausea subjects affected / exposed occurrences (all)	4 / 69 (5.80%) 4	15 / 203 (7.39%) 15	40 / 271 (14.76%) 60
Vomiting subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	2 / 203 (0.99%) 2	28 / 271 (10.33%) 44
Abdominal pain subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	3 / 203 (1.48%) 3	22 / 271 (8.12%) 30
Constipation subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	3 / 203 (1.48%) 3	20 / 271 (7.38%) 20
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1	0 / 203 (0.00%) 0	32 / 271 (11.81%) 41
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	8 / 271 (2.95%) 15
Pruritus			

subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	1 / 203 (0.49%) 1	6 / 271 (2.21%) 6
Eczema subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	5 / 271 (1.85%) 5
Night sweats subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	2 / 271 (0.74%) 15
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	16 / 271 (5.90%) 17
Insomnia subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1	2 / 203 (0.99%) 2	16 / 271 (5.90%) 17
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	20 / 271 (7.38%) 22
Back pain subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1	0 / 203 (0.00%) 0	15 / 271 (5.54%) 17
Pain in extremity subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	13 / 271 (4.80%) 15
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	1 / 203 (0.49%) 1	37 / 271 (13.65%) 52
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	2 / 203 (0.99%) 2	27 / 271 (9.96%) 39
Influenza subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	1 / 203 (0.49%) 1	25 / 271 (9.23%) 29
Bronchitis			

subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	28 / 271 (10.33%) 35
Sinusitis			
subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	19 / 271 (7.01%) 24
Urinary tract infection			
subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	13 / 271 (4.80%) 15
Oral candidiasis			
subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	1 / 203 (0.49%) 1	15 / 271 (5.54%) 18
Gastroenteritis			
subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	1 / 203 (0.49%) 1	9 / 271 (3.32%) 9
Oral herpes			
subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	5 / 271 (1.85%) 5
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	0 / 203 (0.00%) 0	5 / 271 (1.85%) 5

Non-serious adverse events	Non-randomized Cohort-fostemsavir 600 mg BID	Total fostemsavir	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	89 / 99 (89.90%)	296 / 370 (80.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed occurrences (all)	7 / 99 (7.07%) 8	17 / 370 (4.59%) 20	
Skin papilloma			
subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 6	11 / 370 (2.97%) 12	
Nervous system disorders			
Headache			
subjects affected / exposed occurrences (all)	11 / 99 (11.11%) 12	45 / 370 (12.16%) 62	

Dizziness subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 5	20 / 370 (5.41%) 20	
Neuropathy peripheral subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 5	11 / 370 (2.97%) 12	
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	16 / 99 (16.16%) 23	40 / 370 (10.81%) 59	
Fatigue subjects affected / exposed occurrences (all)	16 / 99 (16.16%) 16	33 / 370 (8.92%) 34	
Asthenia subjects affected / exposed occurrences (all)	12 / 99 (12.12%) 12	23 / 370 (6.22%) 24	
Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 5	6 / 370 (1.62%) 6	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	24 / 99 (24.24%) 43	82 / 370 (22.16%) 122	
Nausea subjects affected / exposed occurrences (all)	20 / 99 (20.20%) 28	60 / 370 (16.22%) 88	
Vomiting subjects affected / exposed occurrences (all)	9 / 99 (9.09%) 12	37 / 370 (10.00%) 56	
Abdominal pain subjects affected / exposed occurrences (all)	4 / 99 (4.04%) 4	26 / 370 (7.03%) 34	
Constipation subjects affected / exposed occurrences (all)	6 / 99 (6.06%) 7	26 / 370 (7.03%) 27	

Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	10 / 99 (10.10%) 11	42 / 370 (11.35%) 52	
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Eczema subjects affected / exposed occurrences (all) Night sweats subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 6 5 / 99 (5.05%) 8 5 / 99 (5.05%) 5 5 / 99 (5.05%) 5	13 / 370 (3.51%) 21 11 / 370 (2.97%) 14 10 / 370 (2.70%) 10 7 / 370 (1.89%) 20	
Psychiatric disorders Depression subjects affected / exposed occurrences (all) Insomnia subjects affected / exposed occurrences (all)	3 / 99 (3.03%) 3 3 / 99 (3.03%) 3	19 / 370 (5.14%) 20 19 / 370 (5.14%) 20	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 9 13 / 99 (13.13%) 16 6 / 99 (6.06%) 6	28 / 370 (7.57%) 31 28 / 370 (7.57%) 33 19 / 370 (5.14%) 21	
Infections and infestations			

Upper respiratory tract infection subjects affected / exposed occurrences (all)	13 / 99 (13.13%) 17	50 / 370 (13.51%) 69	
Nasopharyngitis subjects affected / exposed occurrences (all)	16 / 99 (16.16%) 22	43 / 370 (11.62%) 61	
Influenza subjects affected / exposed occurrences (all)	13 / 99 (13.13%) 15	38 / 370 (10.27%) 44	
Bronchitis subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 6	33 / 370 (8.92%) 41	
Sinusitis subjects affected / exposed occurrences (all)	9 / 99 (9.09%) 9	28 / 370 (7.57%) 33	
Urinary tract infection subjects affected / exposed occurrences (all)	10 / 99 (10.10%) 12	23 / 370 (6.22%) 27	
Oral candidiasis subjects affected / exposed occurrences (all)	7 / 99 (7.07%) 8	22 / 370 (5.95%) 26	
Gastroenteritis subjects affected / exposed occurrences (all)	6 / 99 (6.06%) 6	15 / 370 (4.05%) 15	
Oral herpes subjects affected / exposed occurrences (all)	5 / 99 (5.05%) 5	10 / 370 (2.70%) 10	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	8 / 99 (8.08%) 9	13 / 370 (3.51%) 14	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 June 2015	<ul style="list-style-type: none">- Clarify in the protocol that the study will be 96 weeks in duration.- Update with new drug-drug interaction information.- Update with contraception changes.- Update with new Division of AIDS (DAIDS) information for 2014.- Add minor administrative changes.
04 February 2016	<ul style="list-style-type: none">- Clarify the timing of database locks for interim and final analysis of study data, to clarify statistical methods of analysis, and to further define populations for analysis.- Update the anticipated sample size of the randomized and non-randomized cohorts as well as the overall treated population.- Clarify the contraception requirements for Women of Childbearing Potential interested in being treated in the current study.- Updated the list of prohibited concomitant medications.- Updated the names and contact information of the study's medical monitor and study director.- Other minor edits were made to improve the readability of the document.
17 August 2016	<ul style="list-style-type: none">- Identify ViiV Healthcare Company as the sponsor of the study and removed references to Bristol-Myers Squibb (BMS) as the sponsor.- Acknowledge that GlaxoSmithKline (GSK) and Pharmaceutical Product Development (PPD) are supporting ViiV Healthcare in the conduct of the study.- Include the GSK compound number (GSK3684934) and metabolite number (GSK2616713).- Include the GSK study number (205888).- Indicate that molecular analysis will occur at ViiV Healthcare Discovery (Wallingford, CT, USA) instead of at BMS.- Allow study treatment beyond 96 weeks.- Update the endpoints to include a reference to the previously planned interim analysis at Week 48.- Add an interim analysis after the last participant (randomized or non-randomized) completes the Week 96 visit.- Remove InCell Dx sampling at all visits except Screening.- Temporary change in the participant visit schedule to receive study medication every 4 weeks.- Other minor edits were made to improve the readability of the document.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported